aTyr Pharma’s efzofitimod shows immune function in rheumatoid arthritis

aTyr Pharma announced a presentation for its lead therapeutic candidate, efzofitimod, at the American College of Rheumatology Convergence 2023. The data indicate a critical role for NRP2 in modulating immune responses and suggest the potential of efzofitimod as a therapeutic intervention for RA-ILD and potentially other immune-mediated diseases. “These data highlight the broad anti-inflammatory potential of efzofitimod in treating immune-driven conditions and strengthen the evidence that neuropilin-2 – NRP2 – is an important immune regulator,” said Sanjay Shukla, CEO. “Although we remain highly focused on our current clinical development program for efzofitimod in interstitial lung disease, which includes pulmonary sarcoidosis and systemic sclerosis (SSc or scleroderma)-related ILD, this data provides further evidence regarding the potential broader application of efzofitimod in inflammatory diseases beyond these respiratory conditions.”